Executive Summary

1. Proven chemotherapy, made much safer: ONX-1006 uses paclitaxel (PTX), a widely used chemotherapy drug, and is designed to concentrate PTX in tumors while protecting normal cells from PTX exposure.
2. Outstanding safety: In repeat dose GLP toxicity tests, ONX-1006 demonstrated outstanding safety. In the 4-week rat GLP test, the highest dose with no side effects corresponded to more than 750 mg PTX for a 60 kg adult, more than 3.8 times a typical Abraxane dose of about 200 mg PTX.
3. Efficacy: ONX-1006 demonstrated 20% greater tumor reduction than Abraxane at the same weekly PTX dose and the highest level of cancer cell death.
4. Development goals: Continuous treatment for one year or longer without side effect, 90% to 100% tumor elimination, and a 70% one year survival rate.
5. Manufacturing: ONX-1006 has a standardized manufacturing process, with 15 kg of nanoparticles successfully produced.

View or download the full Executive Summary below.

To learn more about Onselex or discuss an investment or strategic partnership, please visit our Investor & Partner page and submit the inquiry form.

Company Video:
https://onselex.com/en/sub/sub04_01.php?boardid=newsen&mode=view&idx=7

Contact:
CureCancer@OnSelex.com